Sponsored by
Tokyo (JCNN) - Chugai Pharmaceutical (TSE: 4519) has announced that it has received approval for expanded indications of Natulan, an antitumor agent, from the Ministry of Health, Labor and Welfare (Japan).
The newly approved agent is now applicable to the treatment of glioma with malignant astrocytoma and oligodendroglioma.
Developed by F. Hoffmann-La Roche, Natulan, a methylhydrazine compound, has been used in the treatment of malignant lymphoma since 1977.